Patents by Inventor Douglas Randall

Douglas Randall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ORAL FORMULATIONS OF LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION
    Publication number: 20250064799
    Abstract: This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of orally administered levosimendan.
    Type: Application
    Filed: December 29, 2022
    Publication date: February 27, 2025
    Applicant: Tenax Therapeutics, Inc.
    Inventors: Stuart Rich, Douglas Randall, Douglas Hay
  • USE OF A COMBINATION OF LEVOSIMENDAN AND AN SGLT-2 INHIBITOR TO TREAT HEART FAILURE
    Publication number: 20250025460
    Abstract: This invention relates to a method of treating heart failure in a human subject comprising administering to the human subject an effective amount of a combination therapy comprising an amount of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof; and an amount of a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.
    Type: Application
    Filed: November 30, 2022
    Publication date: January 23, 2025
    Applicant: Tenax Therapeutics, Inc.
    Inventors: Stuart Rich, Douglas Randall
  • LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF)
    Publication number: 20240269134
    Abstract: This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of levosimendan.
    Type: Application
    Filed: March 29, 2024
    Publication date: August 15, 2024
    Applicant: Tenax Therapeutics, Inc.
    Inventors: Stuart Rich, Douglas Randall, Douglas Hay
  • Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
    Patent number: 11969424
    Abstract: This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of levosimendan.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: April 30, 2024
    Assignee: TENAX THERAPEUTICS, INC.
    Inventors: Stuart Rich, Douglas Randall, Douglas Hay
  • Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
    Patent number: 11701355
    Abstract: This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of levosimendan.
    Type: Grant
    Filed: November 18, 2022
    Date of Patent: July 18, 2023
    Assignee: TENAX THERAPEUTICS, INC.
    Inventors: Stuart Rich, Douglas Randall, Douglas Hay
  • LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF)
    Publication number: 20230107461
    Abstract: This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of levosimendan.
    Type: Application
    Filed: November 18, 2022
    Publication date: April 6, 2023
    Applicant: Tenax Therapeutics, Inc.
    Inventors: Stuart Rich, Douglas Randall, Douglas Hay
  • Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
    Patent number: 11607412
    Abstract: This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of levosimendan.
    Type: Grant
    Filed: August 24, 2021
    Date of Patent: March 21, 2023
    Assignee: TENAX THERAPEUTICS INC.
    Inventors: Stuart Rich, Douglas Randall, Douglas Hay
  • LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF)
    Publication number: 20210393625
    Abstract: This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of levosimendan.
    Type: Application
    Filed: August 24, 2021
    Publication date: December 23, 2021
    Applicant: Tenax Therapeutics, Inc.
    Inventors: Douglas Randall, Douglas Hay
  • LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF)
    Publication number: 20210177840
    Abstract: This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of levosimendan.
    Type: Application
    Filed: December 15, 2020
    Publication date: June 17, 2021
    Applicant: Tenax Therapeutics, Inc.
    Inventors: Douglas Randall, Douglas Hay